Seeking maximum profits, Biogen set an 'unjustifiably high price' for Alzheimer's treatment, investigation finds
By Adam Feuerstein & Damian Garde
House investigation says FDA approval process of Alzheimer's drug was 'rife with irregularities'
By Jen Christensen
Congressional report: U.S. FDA broke own protocols in approving Biogen Alzheimer's drug
By Ahmed Aboulenein
8 takeaways from investigation of Alzheimer's drug approval - STAT
By Adam Feuerstein, Damian Garde & Rachel Cohrs